Bristol Myers Squibb Company $BMY Stock Position Increased by Howard Capital Management LLC

Howard Capital Management LLC boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 168.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,882 shares of the biopharmaceutical company’s stock after buying an additional 77,676 shares during the period. Howard Capital Management LLC’s holdings in Bristol Myers Squibb were worth $7,730,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Boltwood Capital Management lifted its position in shares of Bristol Myers Squibb by 2.5% during the third quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company’s stock worth $443,000 after acquiring an additional 170 shares in the last quarter. Sandy Cove Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 176 shares during the period. Key Financial Inc grew its position in shares of Bristol Myers Squibb by 2.4% in the first quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 183 shares in the last quarter. Cornerstone Planning Group LLC grew its position in shares of Bristol Myers Squibb by 29.8% in the first quarter. Cornerstone Planning Group LLC now owns 801 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 184 shares in the last quarter. Finally, Rosenberg Matthew Hamilton grew its position in shares of Bristol Myers Squibb by 10.5% in the third quarter. Rosenberg Matthew Hamilton now owns 1,933 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 184 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Down 1.4%

BMY traded down $0.88 during trading on Friday, hitting $59.69. 13,770,205 shares of the stock traded hands, compared to its average volume of 14,832,782. The firm has a market capitalization of $121.94 billion, a P/E ratio of 13.15, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a 50-day moving average of $63.55 and a 200 day moving average of $60.29.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the company posted $1.46 EPS. Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.56 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is 55.51%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is currently owned by company insiders.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb’s Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Analysts Set New Price Targets

BMY has been the topic of a number of analyst reports. Royal Bank Of Canada boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $63.00 target price (up from $61.00) on shares of Bristol Myers Squibb in a report on Wednesday, September 23rd. Jefferies Financial Group reiterated a “buy” rating and set a $76.00 price target on shares of Bristol Myers Squibb in a research report on Monday. UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Finally, Roth Capital assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $64.88.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.